These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 4984200)

  • 1. Yellow fever virus. II. Factors affecting the plaque neutralization test.
    Spector SL; Tauraso NM
    Appl Microbiol; 1969 Nov; 18(5):736-43. PubMed ID: 4984200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine.
    Mason RA; Tauraso NM; Spertzel RO; Ginn RK
    Appl Microbiol; 1973 Apr; 25(4):539-44. PubMed ID: 4633476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Yellow fever virus. I. Development and evaluation of a plaque neutralization test.
    Spector S; Tauraso NM
    Appl Microbiol; 1968 Nov; 16(11):1770-5. PubMed ID: 4973067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing antibody responses to varicella-zoster virus.
    Schmidt NJ; Lennette EH
    Infect Immun; 1975 Sep; 12(3):606-13. PubMed ID: 170206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody responses against wild-type yellow fever virus and the 17D vaccine strain: characterization with human monoclonal antibody fragments and neutralization escape variants.
    Daffis S; Kontermann RE; Korimbocus J; Zeller H; Klenk HD; Ter Meulen J
    Virology; 2005 Jul; 337(2):262-72. PubMed ID: 15919103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seroepidemiological survey for yellow fever antibodies in domestic animals.
    Adu F; Esan J; Baba SS
    Rev Roum Virol; 1990; 41(3-4):147-50. PubMed ID: 2099827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers.
    Lindsey NP; Horiuchi KA; Fulton C; Panella AJ; Kosoy OI; Velez JO; Krow-Lucal ER; Fischer M; Staples JE
    J Travel Med; 2018 Jan; 25(1):. PubMed ID: 30346562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Herpesvirus neutralization: the role of complement.
    Wallis C; Melnick JL
    J Immunol; 1971 Nov; 107(5):1235-42. PubMed ID: 5000723
    [No Abstract]   [Full Text] [Related]  

  • 9. Heterologous flavivirus infection-enhancing antibodies in sera of Nigerians.
    Fagbami A; Halstead SB; Marchette N; Larsen K
    Am J Trop Med Hyg; 1988 Jan; 38(1):205-7. PubMed ID: 2829637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralization of yellow fever virus studied using monoclonal and polyclonal antibodies.
    Buckley A; Gould EA
    J Gen Virol; 1985 Dec; 66 ( Pt 12)():2523-31. PubMed ID: 2999305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of MAC-ELISA for evaluation of yellow fever vaccination.
    Nogueira RM; Schatzmayr HG; Miagostovich MP; Cavalcanti SM; de Carvalho R
    Rev Inst Med Trop Sao Paulo; 1992; 34(5):447-50. PubMed ID: 1342109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of complement and viral filtration on the neutralization of respiratory syncytial virus.
    Baughman RH; Fenters JD; Marquis GS; Holper JC
    Appl Microbiol; 1968 Jul; 16(7):1076-80. PubMed ID: 5664124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing F(ab')2 fragments of protective monoclonal antibodies to yellow fever virus (YF) envelope protein fail to protect mice against lethal YF encephalitis.
    Schlesinger JJ; Chapman S
    J Gen Virol; 1995 Jan; 76 ( Pt 1)():217-20. PubMed ID: 7844536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibodies distinguish between wild and vaccine strains of yellow fever virus by neutralization, hemagglutination inhibition, and immune precipitation of the virus envelope protein.
    Schlesinger JJ; Brandriss MW; Monath TP
    Virology; 1983 Feb; 125(1):8-17. PubMed ID: 6187129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.
    Monath TP; Soike K; Levenbook I; Zhang ZX; Arroyo J; Delagrave S; Myers G; Barrett AD; Shope RE; Ratterree M; Chambers TJ; Guirakhoo F
    Vaccine; 1999 Apr; 17(15-16):1869-82. PubMed ID: 10217584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro studies with Modoc virus in Vero cells: plaque assay and kinetics of growth, neutralization, and thermal inactivation.
    Davis JW; Hardy JL
    Appl Microbiol; 1973 Sep; 26(3):344-8. PubMed ID: 4201641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complement-mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C virus E2 chimeric glycoprotein.
    Meyer K; Basu A; Przysiecki CT; Lagging LM; Di Bisceglie AM; Conley AJ; Ray R
    J Virol; 2002 Mar; 76(5):2150-8. PubMed ID: 11836392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pressure-inactivated yellow fever 17DD virus: implications for vaccine development.
    Gaspar LP; Mendes YS; Yamamura AM; Almeida LF; Caride E; Gonçalves RB; Silva JL; Oliveira AC; Galler R; Freire MS
    J Virol Methods; 2008 Jun; 150(1-2):57-62. PubMed ID: 18420285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement-requiring neutralizing antibody in guinea pigs with primary and recurrent genital herpes.
    Zheng ZM; Hsiung GD
    Proc Soc Exp Biol Med; 1984 Nov; 177(2):332-6. PubMed ID: 6091148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Yellow fever vaccine. V. Antibody response in maonkeys inoculated with graded doses of the 17D vaccine.
    Mason RA; Tauraso NM; Ginn RK; O'Brien TC; Trimmer RW
    Appl Microbiol; 1972 May; 23(5):908-13. PubMed ID: 4624211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.